Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Ḧurthle-cell neoplasms of the thyroid

Insoo Suh, Menno R. Vriens, Marlon A Guerrero, Ann Griffin, Wen T. Shen, Quan Yang Duh, Orlo H. Clark, Electron Kebebew

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background: Serum thyroglobulin (Tg) is the most accurate biomarker for thyroid cancer recurrence. However, some clinicians measure preoperative Tg as a diagnostic cancer marker despite lack of supporting evidence. We examined whether Tg accurately predicts malignancy in follicular or Hürthle-cell neoplasms. Methods: We reviewed 366 patients who underwent thyroidectomies for follicular/Hürthle-cell neoplasms. We compared Tg in malignant versus benign tumors by univariate and receiver-operator characteristic analyses. We also examined several Tg-derived indices that normalized Tg to known confounding factors including nodule size, thyroid function, and type of Tg assay. Results: Thirty-nine patients met inclusion criteria for analysis. There were no differences between malignant (n = 16) and benign (n = 23) lesions in Tg or any of the normalized indexes. Receiver-operator characteristic analysis revealed an area under the curve of .59. Lesions with Tg levels greater than 500 μg/L had a positive predictive value of .75. Conclusions: Tg has poor accuracy for predicting malignancy in follicular or Hürthle-cell thyroid neoplasms.

Original languageEnglish (US)
Pages (from-to)41-46
Number of pages6
JournalAmerican Journal of Surgery
Volume200
Issue number1
DOIs
StatePublished - Jul 2010
Externally publishedYes

Fingerprint

Thyroglobulin
Thyroid Neoplasms
Biomarkers
Serum
Neoplasms
Thyroid Nodule
Thyroidectomy
Area Under Curve
Recurrence

Keywords

  • Biological markers
  • Follicular thyroid neoplasms
  • Hürthle-cell thyroid neoplasms
  • Thyroglobulin
  • Thyroid nodules

ASJC Scopus subject areas

  • Surgery

Cite this

Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Ḧurthle-cell neoplasms of the thyroid. / Suh, Insoo; Vriens, Menno R.; Guerrero, Marlon A; Griffin, Ann; Shen, Wen T.; Duh, Quan Yang; Clark, Orlo H.; Kebebew, Electron.

In: American Journal of Surgery, Vol. 200, No. 1, 07.2010, p. 41-46.

Research output: Contribution to journalArticle

Suh, Insoo ; Vriens, Menno R. ; Guerrero, Marlon A ; Griffin, Ann ; Shen, Wen T. ; Duh, Quan Yang ; Clark, Orlo H. ; Kebebew, Electron. / Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Ḧurthle-cell neoplasms of the thyroid. In: American Journal of Surgery. 2010 ; Vol. 200, No. 1. pp. 41-46.
@article{e1c3d536a9944da5b4e22e0ea94d5fbd,
title = "Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Ḧurthle-cell neoplasms of the thyroid",
abstract = "Background: Serum thyroglobulin (Tg) is the most accurate biomarker for thyroid cancer recurrence. However, some clinicians measure preoperative Tg as a diagnostic cancer marker despite lack of supporting evidence. We examined whether Tg accurately predicts malignancy in follicular or H{\"u}rthle-cell neoplasms. Methods: We reviewed 366 patients who underwent thyroidectomies for follicular/H{\"u}rthle-cell neoplasms. We compared Tg in malignant versus benign tumors by univariate and receiver-operator characteristic analyses. We also examined several Tg-derived indices that normalized Tg to known confounding factors including nodule size, thyroid function, and type of Tg assay. Results: Thirty-nine patients met inclusion criteria for analysis. There were no differences between malignant (n = 16) and benign (n = 23) lesions in Tg or any of the normalized indexes. Receiver-operator characteristic analysis revealed an area under the curve of .59. Lesions with Tg levels greater than 500 μg/L had a positive predictive value of .75. Conclusions: Tg has poor accuracy for predicting malignancy in follicular or H{\"u}rthle-cell thyroid neoplasms.",
keywords = "Biological markers, Follicular thyroid neoplasms, H{\"u}rthle-cell thyroid neoplasms, Thyroglobulin, Thyroid nodules",
author = "Insoo Suh and Vriens, {Menno R.} and Guerrero, {Marlon A} and Ann Griffin and Shen, {Wen T.} and Duh, {Quan Yang} and Clark, {Orlo H.} and Electron Kebebew",
year = "2010",
month = "7",
doi = "10.1016/j.amjsurg.2009.08.030",
language = "English (US)",
volume = "200",
pages = "41--46",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Ḧurthle-cell neoplasms of the thyroid

AU - Suh, Insoo

AU - Vriens, Menno R.

AU - Guerrero, Marlon A

AU - Griffin, Ann

AU - Shen, Wen T.

AU - Duh, Quan Yang

AU - Clark, Orlo H.

AU - Kebebew, Electron

PY - 2010/7

Y1 - 2010/7

N2 - Background: Serum thyroglobulin (Tg) is the most accurate biomarker for thyroid cancer recurrence. However, some clinicians measure preoperative Tg as a diagnostic cancer marker despite lack of supporting evidence. We examined whether Tg accurately predicts malignancy in follicular or Hürthle-cell neoplasms. Methods: We reviewed 366 patients who underwent thyroidectomies for follicular/Hürthle-cell neoplasms. We compared Tg in malignant versus benign tumors by univariate and receiver-operator characteristic analyses. We also examined several Tg-derived indices that normalized Tg to known confounding factors including nodule size, thyroid function, and type of Tg assay. Results: Thirty-nine patients met inclusion criteria for analysis. There were no differences between malignant (n = 16) and benign (n = 23) lesions in Tg or any of the normalized indexes. Receiver-operator characteristic analysis revealed an area under the curve of .59. Lesions with Tg levels greater than 500 μg/L had a positive predictive value of .75. Conclusions: Tg has poor accuracy for predicting malignancy in follicular or Hürthle-cell thyroid neoplasms.

AB - Background: Serum thyroglobulin (Tg) is the most accurate biomarker for thyroid cancer recurrence. However, some clinicians measure preoperative Tg as a diagnostic cancer marker despite lack of supporting evidence. We examined whether Tg accurately predicts malignancy in follicular or Hürthle-cell neoplasms. Methods: We reviewed 366 patients who underwent thyroidectomies for follicular/Hürthle-cell neoplasms. We compared Tg in malignant versus benign tumors by univariate and receiver-operator characteristic analyses. We also examined several Tg-derived indices that normalized Tg to known confounding factors including nodule size, thyroid function, and type of Tg assay. Results: Thirty-nine patients met inclusion criteria for analysis. There were no differences between malignant (n = 16) and benign (n = 23) lesions in Tg or any of the normalized indexes. Receiver-operator characteristic analysis revealed an area under the curve of .59. Lesions with Tg levels greater than 500 μg/L had a positive predictive value of .75. Conclusions: Tg has poor accuracy for predicting malignancy in follicular or Hürthle-cell thyroid neoplasms.

KW - Biological markers

KW - Follicular thyroid neoplasms

KW - Hürthle-cell thyroid neoplasms

KW - Thyroglobulin

KW - Thyroid nodules

UR - http://www.scopus.com/inward/record.url?scp=77955461906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955461906&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2009.08.030

DO - 10.1016/j.amjsurg.2009.08.030

M3 - Article

C2 - 20637335

AN - SCOPUS:77955461906

VL - 200

SP - 41

EP - 46

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 1

ER -